Asthma treatments that focused on blocking Type 2 cytokines (IL-4, IL-5, and IL-13) decrease blood or sputum eosinophil counts and asthma symptoms in subjects with severe asthma presenting a high eosinophil count in their induced sputum (11–25). Here, IL4 is linked to asthma.